The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA approval for sleep apnea is based on two company-sponsored trials encompassing about 470 participants, one in which ...

When Julianna Moore wanted to start her day, she knew just how to wake up her parents: curling her toes. Diagnosed with ...

Looking for a new portable power station? Power stations are must-have backup power solutions for your home if you're ...

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

If the cost of waking up with the most dewy and glowing skin meant you had to layer on “ugly” products the night before, ...

The FDA has granted approval for its first medication for certain patients with sleep apnea—the weight-loss drug Zepbound.

OSA is usually treated with a mask worn during sleep, called a continuous positive airway pressure (CPAP) machine. Credit ... Eli Lilly reported combined sales of $5.4bn for Zepbound and Mounjaro in ...

The excessive daytime sleepiness market drowsiness was projected to be worth USD 4.9 billion in 2022. With an expected CAGR of 8.8% from 2023 to 2033, this market is expected to earn USD 5.33 billion ...

As a young personal trainer, Ben Carpenter became increasingly aware of a rising wave of misinformation about diet and ...